Movatterモバイル変換


[0]ホーム

URL:


PhilPapersPhilPeoplePhilArchivePhilEventsPhilJobs
Order:

1 filter applied
  1.  101
    Ethical Challenges Arising in the COVID-19 Pandemic: An Overview from the Association of Bioethics Program Directors (ABPD) Task Force.Amy L. McGuire,Mark P. Aulisio,F. Daniel Davis,Cheryl Erwin,Thomas D. Harter,Reshma Jagsi,Robert Klitzman,Robert Macauley,Eric Racine,Susan M. Wolf,Matthew Wynia &Paul Root Wolpe -2020 -American Journal of Bioethics 20 (7):15-27.
    The COVID-19 pandemic has raised a host of ethical challenges, but key among these has been the possibility that health care systems might need to ration scarce critical care resources. Rationing p...
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   40 citations  
  2.  54
    Researcher Views on Changes in Personality, Mood, and Behavior in Next-Generation Deep Brain Stimulation.Peter Zuk,Clarissa E. Sanchez,Kristin Kostick-Quenet,Katrina A. Muñoz,Lavina Kalwani,Richa Lavingia,Laura Torgerson,Demetrio Sierra-Mercado,Jill O. Robinson,Stacey Pereira,Simon Outram,Barbara A. Koenig,Amy L. McGuire &Gabriel Lázaro-Muñoz -2023 -American Journal of Bioethics Neuroscience 14 (3):287-299.
    The literature on deep brain stimulation (DBS) and adaptive DBS (aDBS) raises concerns that these technologies may affect personality, mood, and behavior. We conducted semi-structured interviews with researchers (n = 23) involved in developing next-generation DBS systems, exploring their perspectives on ethics and policy topics including whether DBS/aDBS can cause such changes. The majority of researchers reported being aware of personality, mood, or behavioral (PMB) changes in recipients of DBS/aDBS. Researchers offered varying estimates of the frequency of PMB changes. A (...) smaller majority reported changes in personality specifically. Some expressed reservations about the scientific status of the term ‘personality,’ while others used it freely. Most researchers discussed negative PMB changes, but a majority said that DBS/aDBS can also result in positive changes. Several researchers viewed positive PMB changes as part of the therapeutic goal in psychiatric applications of DBS/aDBS. Finally, several discussed potential causes of PMB changes other than the device itself. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   14 citations  
  3.  48
    Ethics Education for Healthcare Professionals in the Era of ChatGPT and Other Large Language Models: Do We Still Need It?Vasiliki Rahimzadeh,Kristin Kostick-Quenet,Jennifer Blumenthal Barby &Amy L. McGuire -2023 -American Journal of Bioethics 23 (10):17-27.
    ChatGPT has taken the academic community by storm (Cotton, Cotton, and Shipway 2023; Cox and Tzoc 2023; Sullivan, Kelly, and McLaughlan 2023). Since its release in November 2022, chatGPT has predic...
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   12 citations  
  4.  258
    A Transformative Trip? Experiences of Psychedelic Use.Logan Neitzke-Spruill,Caroline Beit,Jill Robinson,Kai Blevins,Joel Reynolds,Nicholas G. Evans &Amy L. McGuire -2024 -Neuroethics 17 (33):1-21.
    Psychedelic experiences are often compared to “transformative experiences” due to their potential to change how people think and behave. This study empirically examines whether psychedelic experiences constitute transformative experiences. Given psychedelics’ prospective applications as treatments for mental health disorders, this study also explores neuroethical issues raised by the possibility of biomedically directed transformation—namely, consent and moral psychopharmacology. To achieve these aims, we used both inductive and deductive coding techniques to analyze transcripts from interviews with 26 participants in psychedelic retreats. Results (...) indicate that psychedelic experiences can constitute transformative experiences. Twenty participants reported experiences or insights that were seemingly inaccessible or impossible to attain if not for the psychoactive effects of psychedelics. All participants besides one reported some change in identity, values, beliefs, desires, and behavior—changes in behavior being the most common. Participants also reported feeling capable deciding to use psychedelics in part due to information seeking prior to their retreats. Finally, several participants reported an enhanced capacity for enacting changes in their lives. Our results underscore both the importance of subjective embodiment to transformation and the role of transformative agency in shaping outcomes of the psychedelic experience. We examine our results relative to neuroethical issues and advocate for centering the person in psychedelic research and neuroethical inquiry about psychedelics to avoid pitfalls associated with psychedelics’ potential as moral psychopharmacological agents. (shrink)
    Direct download(5 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  5.  60
    Are Psychedelic Experiences Transformative? Can We Consent to Them?Brent M. Kious,Andrew Peterson &Amy L. McGuire -2024 -Perspectives in Biology and Medicine 67 (1):143-154.
    ABSTRACT:Psychedelic substances have great promise for the treatment of many conditions, and they are the subject of intensive research. As with other medical treatments, both research and clinical use of psychedelics depend on our ability to ensure informed consent by patients and research participants. However, some have argued that informed consent for psychedelic use may be impossible, because psychedelic experiences can be transformative in the sense articulated by L. A. Paul (2014). For Paul, transformative experiences involve either the acquisition of (...) knowledge that cannot be obtained in any other way or changes in the self. Either of these characteristics may appear to undermine informed consent. This article argues, however, that there is limited evidence that psychedelic experiences are transformative in Paul's sense, and that they may not differ in their transformative features from other common medical experiences for which informed consent is clearly possible. Further, even if psychedelic experiences can be transformative, informed consent is still possible. Because psychedelic experiences are importantly different in several respects from other medical experiences, this article closes with recommendations for how these differences should be reflected in informed consent processes. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   5 citations  
  6.  34
    Deciding with Others: Interdependent Decision‐Making.Emily A. Largent,Justin Clapp,Jennifer S. Blumenthal-Barby,Christine Grady,Amy L. McGuire,Jason Karlawish,Joshua D. Grill,Shana D. Stites &Andrew Peterson -2022 -Hastings Center Report 52 (6):23-32.
    Over the course of human life, health care decision‐making is often interdependent. In this article, we use “interdependence” to refer to patients’ engagement of nonclinicians—for example, family members or trusted friends—to reach health care decisions. Interdependence, we suggest, is common for patients in all stages of life, from early childhood to late adulthood. This view contrasts with the common bioethical assumption that medical decisions are either wholly independent or dependent and that independence or dependence is tightly coupled with a person's (...) decision‐making capacity. In this article, we array various approaches to decision‐making along a continuum of interdependence. An appreciation of this continuum can empower patients and elucidate ethical challenges that arise when people transition between different kinds of interdependence across the life span. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  7.  83
    Introduction: Sharing Data in a Medical Information Commons.Amy L. McGuire,Mary A. Majumder,Angela G. Villanueva,Jessica Bardill,Juli M. Bollinger,Eric Boerwinkle,Tania Bubela,Patricia A. Deverka,Barbara J. Evans,Nanibaa' A. Garrison,David Glazer,Melissa M. Goldstein,Henry T. Greely,Scott D. Kahn,Bartha M. Knoppers,Barbara A. Koenig,J. Mark Lambright,John E. Mattison,Christopher O'Donnell,Arti K. Rai,Laura L. Rodriguez,Tania Simoncelli,Sharon F. Terry,Adrian M. Thorogood,Michael S. Watson,John T. Wilbanks &Robert Cook-Deegan -2019 -Journal of Law, Medicine and Ethics 47 (1):12-20.
    Drawing on a landscape analysis of existing data-sharing initiatives, in-depth interviews with expert stakeholders, and public deliberations with community advisory panels across the U.S., we describe features of the evolving medical information commons. We identify participant-centricity and trustworthiness as the most important features of an MIC and discuss the implications for those seeking to create a sustainable, useful, and widely available collection of linked resources for research and other purposes.
    Direct download(3 more)  
     
    Export citation  
     
    Bookmark   7 citations  
  8.  25
    Bio-Psycho-Spiritual Perspectives on Psychedelics: Clinical and Ethical Implications.Logan Neitzke-Spruill,Nese Devenot,Dominic Sisti,Lynnette A. Averill &Amy L. McGuire -2024 -Perspectives in Biology and Medicine 67 (1):117-142.
    ABSTRACT:Psychedelics have again become a subject of widespread interest, owing to the reinvigoration of research into their traditional uses, possible medical applications, and social implications. As evidence for psychedelics' clinical potential mounts, the field has increasingly focused on searching for mechanisms to explain the effects of psychedelics and therapeutic efficacy of psychedelic-assisted therapy (PAT). This paper reviews three general frameworks that encompass several prominent models for understanding psychedelics' effects—specifically, neurobiological, psychological, and spiritual frameworks. Following our review, the implications of each (...) framework for ethics and professional competencies in the implementation of psychedelics as medicines are explored. We suggest that interdisciplinary education may be necessary to improve communication between researchers, develop models that effectively incorporate multiple levels of analysis, and facilitate collaboration between professionals with diverse backgrounds in the implementation of psychedelic medicines. We also address pitfalls associated with overemphasis on neuro-mechanisms, risks associated with instigating vulnerable states of consciousness, and hurdles associated with the integration of spiritual frameworks in medicine. Ultimately, as psychedelics push the boundaries of explanatory frameworks focused on one level of analysis, developing new and more useful models to reflect knowledge being produced in this field should be a central aim of psychedelic science going forward. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  9.  42
    Neuroethics at 15: Keep the Kant but Add More Bacon.Gabriel Lázaro-Muñoz,Peter Zuk,Stacey Pereira,Kristin Kostick,Laura Torgerson,Demetrio Sierra-Mercado,Mary Majumder,J. Blumenthal-Barby,Eric A. Storch,Wayne K. Goodman &Amy L. McGuire -2019 -American Journal of Bioethics Neuroscience 10 (3):97-100.
  10.  2
    Supportive Touch in Psychedelic Assisted Therapy.Logan Neitzke-Spruill,Caroline Beit,Lynnette A. Averill &Amy L. McGuire -2025 -American Journal of Bioethics 25 (1):29-39.
    In August 2024, The U.S. Food and Drug Administration rejected Lykos Therapeutics, Inc.'s new drug application for midomafetamine with psychological intervention (MDMA-AT) to treat post-traumatic stress disorder (PTSD). Among the many issues raised during review was concern about a highly publicized case of alleged sexual misconduct by an unlicensed therapist during a Phase 2 study of MDMA and the potential risk of future abuse. This incident of misconduct, along with several other publicized cases of misconduct by guides, facilitators, and shaman (...) offering psychedelic retreats, has raised the question of whether physical contact is ever appropriate during psychedelic-assisted therapy (PAT). Drawing on research about supportive touch in other clinical contexts and taking into consideration features of psychedelics that exacerbate the potential for harm associated with supportive touch, we advocate for a precautionary approach to harm-reduction while arguing that supportive touch ought not be thrown out whole-cloth. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   5 citations  
  11.  59
    What is a Medical Information Commons?Juli M. Bollinger,Peter D. Zuk,Mary A. Majumder,Erika Versalovic,Angela G. Villanueva,Rebecca L. Hsu,Amy L. McGuire &Robert Cook-Deegan -2019 -Journal of Law, Medicine and Ethics 47 (1):41-50.
    A 2011 National Academies of Sciences report called for an “Information Commons” and a “Knowledge Network” to revolutionize biomedical research and clinical care. We interviewed 41 expert stakeholders to examine governance, access, data collection, and privacy in the context of a medical information commons. Stakeholders' attitudes about MICs align with the NAS vision of an Information Commons; however, differences of opinion regarding clinical use and access warrant further research to explore policy and technological solutions.
    Direct download(3 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  12.  50
    Genomic Data-Sharing Practices.Angela G. Villanueva,Robert Cook-Deegan,Jill O. Robinson,Amy L. McGuire &Mary A. Majumder -2019 -Journal of Law, Medicine and Ethics 47 (1):31-40.
    Making data broadly accessible is essential to creating a medical information commons. Transparency about data-sharing practices can cultivate trust among prospective and existing MIC participants. We present an analysis of 34 initiatives sharing DNA-derived data based on public information. We describe data-sharing practices captured, including practices related to consent, privacy and security, data access, oversight, and participant engagement. Our results reveal that data-sharing initiatives have some distance to go in achieving transparency.
    Direct download(3 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  13.  47
    Who Owns the Data in a Medical Information Commons?Amy L. McGuire,Jessica Roberts,Sean Aas &Barbara J. Evans -2019 -Journal of Law, Medicine and Ethics 47 (1):62-69.
    In this paper, we explore the perspectives of expert stakeholders about who owns data in a medical information commons and what rights and interests ought to be recognized when developing a governance structure for an MIC. We then examine the legitimacy of these claims based on legal and ethical analysis and explore an alternative framework for thinking about participants' rights and interests in an MIC.
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   5 citations  
  14.  46
    Researcher Perspectives on Data Sharing in Deep Brain Stimulation.Peter Zuk,Clarissa E. Sanchez,Kristin Kostick,Laura Torgerson,Katrina A. Muñoz,Rebecca Hsu,Lavina Kalwani,Demetrio Sierra-Mercado,Jill O. Robinson,Simon Outram,Barbara A. Koenig,Stacey Pereira,Amy L. McGuire &Gabriel Lázaro-Muñoz -2020 -Frontiers in Human Neuroscience 14:578687.
    The expansion of research on deep brain stimulation (DBS) and adaptive DBS (aDBS) raises important neuroethics and policy questions related to data sharing. However, there has been little empirical research on the perspectives of experts developing these technologies. We conducted semi-structured, open-ended interviews with aDBS researchers regarding their data sharing practices and their perspectives on ethical and policy issues related to sharing. Researchers expressed support for and a commitment to sharing, with most saying that they were either sharing their data (...) or would share in the future and that doing so was important for advancing the field. However, those who are sharing reported a variety of sharing partners, suggesting heterogeneity in sharing practices and lack of the broad sharing that would reflect principles of open science. Researchers described several concerns and barriers related to sharing, including privacy and confidentiality, the usability of shared data by others, ownership and control of data (including potential commercialization), and limited resources for sharing. They also suggested potential solutions to these challenges, including additional safeguards to address privacy issues, standardization and transparency in analysis to address issues of data usability, professional norms and heightened cooperation to address issues of ownership and control, and streamlining of data transmission to address resource limitations. Researchers also offered a range of views on the sensitivity of neural activity data (NAD) and data related to mental health in the context of sharing. These findings are an important input to deliberations by researchers, policymakers, neuroethicists, and other stakeholders as they navigate ethics and policy questions related to aDBS research. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  15.  47
    Alienation, Quality of Life, and DBS for Depression.Peter Zuk,Amy L. McGuire &Gabriel Lázaro-Muñoz -2018 -American Journal of Bioethics Neuroscience 9 (4):223-225.
  16.  48
    Hopeful and Concerned: Public Input on Building a Trustworthy Medical Information Commons.Patricia A. Deverka,Dierdre Gilmore,Jennifer Richmond,Zachary Smith,Rikki Mangrum,Barbara A. Koenig,Robert Cook-Deegan,Angela G. Villanueva,Mary A. Majumder &Amy L. McGuire -2019 -Journal of Law, Medicine and Ethics 47 (1):70-87.
    A medical information commons is a networked data environment utilized for research and clinical applications. At three deliberations across the U.S., we engaged 75 adults in two-day facilitated discussions on the ethical and social issues inherent to sharing data with an MIC. Deliberants made recommendations regarding opt-in consent, transparent data policies, public representation on MIC governing boards, and strict data security and privacy protection. Community engagement is critical to earning the public's trust.
    Direct download(3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  17.  36
    Characterizing the Biomedical Data-Sharing Landscape.Angela G. Villanueva,Robert Cook-Deegan,Barbara A. Koenig,Patricia A. Deverka,Erika Versalovic,Amy L. McGuire &Mary A. Majumder -2019 -Journal of Law, Medicine and Ethics 47 (1):21-30.
    Advances in technologies and biomedical informatics have expanded capacity to generate and share biomedical data. With a lens on genomic data, we present a typology characterizing the data-sharing landscape in biomedical research to advance understanding of the key stakeholders and existing data-sharing practices. The typology highlights the diversity of data-sharing efforts and facilitators and reveals how novel data-sharing efforts are challenging existing norms regarding the role of individuals whom the data describe.
    Direct download(3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  18.  147
    Integrating Rules for Genomic Research, Clinical Care, Public Health Screening and DTC Testing: Creating Translational Law for Translational Genomics.Susan M. Wolf,Pilar N. Ossorio,Susan A. Berry,Henry T. Greely,Amy L. McGuire,Michelle A. Penny &Sharon F. Terry -2020 -Journal of Law, Medicine and Ethics 48 (1):69-86.
    Human genomics is a translational field spanning research, clinical care, public health, and direct-to-consumer testing. However, law differs across these domains on issues including liability, consent, promoting quality of analysis and interpretation, and safeguarding privacy. Genomic activities crossing domains can thus encounter confusion and conflicts among these approaches. This paper suggests how to resolve these conflicts while protecting the rights and interests of individuals sequenced. Translational genomics requires this more translational approach to law.
    Direct download(3 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  19.  57
    When bins blur: Patient perspectives on categories of results from clinical whole genome sequencing.Leila Jamal,Jill O. Robinson,Kurt D. Christensen,Jennifer Blumenthal-Barby,Melody J. Slashinski,Denise Lautenbach Perry,Jason L. Vassy,Julia Wycliff,Robert C. Green &Amy L. McGuire -2017 -AJOB Empirical Bioethics 8 (2):82-88.
    No categories
    Direct download  
     
    Export citation  
     
    Bookmark   4 citations  
  20.  34
    Biomedical Citizen Science or Something Else? Reflections on Terms and Definitions.Christi J. Guerrini,Anna Wexler,Patricia J. Zettler &Amy L. McGuire -2019 -American Journal of Bioethics 19 (8):17-19.
    In their article “The Rise of Citizen Science in Health and Biomedical Research,” Wiggins and Wilbanks (2019) present a new typology for understanding the complex landscape of health and biomedical...
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  21.  29
    Donors, authors, and owners: how is genomic citizen science addressing interests in research outputs?Christi J. Guerrini,Meaganne Lewellyn,Mary A. Majumder,Meredith Trejo,Isabel Canfield &Amy L. McGuire -2019 -BMC Medical Ethics 20 (1):1-13.
    Background Citizen science is increasingly prevalent in the biomedical sciences, including the field of human genomics. Genomic citizen science initiatives present new opportunities to engage individuals in scientific discovery, but they also are provoking new questions regarding who owns the outputs of the research, including intangible ideas and discoveries and tangible writings, tools, technologies, and products. The legal and ethical claims of participants to research outputs become stronger—and also more likely to conflict with those of institution-based researchers and other stakeholders—as (...) participants become more involved, quantitatively and qualitatively, in the research process. It is not yet known, however, how genomic citizen science initiatives are managing the interests of their participants in accessing and controlling research outputs in practice. To help fill this gap, we conducted an in-depth review of relevant policies and practices of U.S.-based genomic citizen science initiatives. Methods We queried the peer-reviewed literature and grey literature to identify 22 genomic citizen science initiatives that satisfied six inclusion criteria. A data collection form was used to capture initiative features, policies, and practices relevant to participants’ access to and control over research outputs. Results This analysis revealed that the genomic citizen science landscape is diverse and includes many initiatives that do not have institutional affiliations. Two trends that are in apparent tension were identified: commercialization and operationalization of a philosophy of openness. While most initiatives supported participants’ access to research outputs, including datasets and published findings, none supported participants’ control over results via intellectual property, licensing, or commercialization rights. However, several initiatives disclaimed their own rights to profit from outputs. Conclusions There are opportunities for citizen science initiatives to incorporate more features that support participants’ access to and control over research outputs, consistent with their specific objectives, operations, and technical capabilities. (shrink)
    Direct download(4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  22.  97
    Currents in Contemporary Ethics.Cynthia Marietta &Amy L. McGuire -2009 -Journal of Law, Medicine and Ethics 37 (2):369-374.
    Understanding of the human genome and its functional significance has increased exponentially since the completion of the Human Genome Project in 2003. The HGP fueled the discovery of more than 1,800 disease genes and paved the way for researchers to identify and test for genes suspected of causing inherited diseases. Currently, there are more than 1000 genetic tests for human diseases and conditions on the market. These tests can play an integral role in the delivery of health care by providing (...) information that could potentially form the basis for profound life decisions, such as whether to undergo a prophylactic mastectomy, whether to terminate a pregnancy, or whether to take a particular drug or medication dose. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  23.  30
    Identifiability of DNA Data: The Need for Consistent Federal Policy.Amy L. McGuire -2008 -American Journal of Bioethics 8 (10):75-76.
    Biological samples are routinely collected and used in biomedical research. As Weir and Olick (2004) point out in their book The Stored Tissue Issue, there are four ways in which samples can be sto...
    Direct download(4 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  24.  54
    Consent: Informed, Simple, Implied and Presumed.Laurence B. McCullough,Amy L. McGuire &Simon N. Whitney -2007 -American Journal of Bioethics 7 (12):49-50.
  25.  27
    Data Sharing in the Context of Health-Related Citizen Science.Mary A. Majumder &Amy L. McGuire -2020 -Journal of Law, Medicine and Ethics 48 (S1):167-177.
    As citizen science expands, questions arise regarding the applicability of norms and policies created in the context of conventional science. This article focuses on data sharing in the conduct of health-related citizen science, asking whether citizen scientists have obligations to share data and publish findings on par with the obligations of professional scientists. We conclude that there are good reasons for supporting citizen scientists in sharing data and publishing findings, and we applaud recent efforts to facilitate data sharing. At the (...) same time, we believe it is problematic to treat data sharing and publication as ethical requirements for citizen scientists, especially where there is the potential for burden and harm without compensating benefit. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  26.  37
    A Right to Privacy and Confidentiality: Ethical Medical Care for Patients in United States Immigration Detention.Amanda M. Gutierrez,Jacob D. Hofstetter,Emma L. Dishner,Elizabeth Chiao,Dilreet Rai &Amy L. McGuire -2020 -Journal of Law, Medicine and Ethics 48 (1):161-168.
    Recently, John Doe, an undocumented immigrant who was detained by United States Immigration and Customs Enforcement, was admitted to a hospital off-site from a detention facility. Custodial officers accompanied Mr. Doe into the exam room and refused to leave as physicians examined him. In this analysis, we examine the ethical dilemmas this case brings to light concerning the treatment of patients in immigration detention and their rights to privacy. We analyze what US law and immigration detention standards allow regarding immigration (...) enforcement or custodial officers’ presence in medical exams and documentation of detainee health information. We describe the ethical implications of the presence of officers in medical exam rooms, including its effects on the quality of the patient-provider relationship, patient privacy and confidentiality, and provider's ability to provide ethical care. We conclude that the presence of immigration enforcement or custodial officers during medical examination of detainees is a breach of the right to privacy of detainees who are not an obvious threat to the public. We urge ICE and the US Department of Homeland Security to clarify standards for and tighten enforcement around when officers are legally allowed to be stationed in medical exam rooms and document detainees’ information. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  27.  30
    Public Perspectives on Investigative Genetic Genealogy: Findings from a National Focus Group Study.Jacklyn Dahlquist,Jill O. Robinson,Amira Daoud,Whitney Bash-Brooks,Amy L. McGuire,Christi J. Guerrini &Stephanie M. Fullerton -2024 -AJOB Empirical Bioethics 15 (4):280-290.
    Background Investigative genetic genealogy (IGG) is a technique that involves uploading genotypes developed from perpetrator DNA left at a crime scene, or DNA from unidentified remains, to public genetic genealogy databases to identify genetic relatives and, through the creation of a family tree, the individual who was the source of the DNA. As policymakers demonstrate interest in regulating IGG, it is important to understand public perspectives on IGG to determine whether proposed policies are aligned with public attitudes.Methods We conducted eight (...) focus groups with members of the public (N = 72), sampled from four geographically diverse US regions, to explore general attitudes and perspectives regarding aspects of IGG practices, applications, and policies. Five major topics were explored in each focus group: when IGG should be used; who should perform IGG; how to approach consent for genetic database users; what systems of oversight should govern IGG practitioners; and whether to notify database users if their data are involved in law enforcement (LE) matching.Results Participants were supportive of IGG in most scenarios, especially for cold and violent cases. The favorable attitudes toward IGG were, however, tempered by distrust of law enforcement among some participants. All participants agreed that databases must inform users if IGG is allowed, but they did not agree on how individual database users should be allowed to opt out or whether to notify them if their data are involved in specific investigations. All participants agreed that IGG should be subject to some prescriptive guidelines, regulations, or accountability mechanisms.Conclusions These findings suggest broad public support for IGG, and interest in developing systems of accountability for its practice. Our study provides useful insight for policy makers, genomic database stewards, law enforcement, and other stakeholders in IGG’s practice, and suggests multiple directions for future research. (shrink)
    No categories
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark  
  28.  11
    “A Double-Edged Sword”: A Brief History of Genomic Data Governance and Genetic Researcher Perspectives on Data Sharing.Kayte Spector-Bagdady,Kerry A. Ryan,Amy L. McGuire,Chris D. Krenz,M. Grace Trinidad,Kaitlyn Jaffe,Amanda Greene,J. Denard Thomas,Madison Kent,Stephanie Morain,David Wilborn &J. Scott Roberts -2024 -Journal of Law, Medicine and Ethics 52 (2):399-411.
    As the federal government continues to expand upon and improve its data sharing policies over the past 20 years, complex challenges remain. Our interviews with U.S. academic genetic researchers (n=23) found that the burden, translation, industry limitations, and consent structure of data sharing remain major governance challenges.
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark  
  29.  36
    “Idealists and capitalists”: ownership attitudes and preferences in genomic citizen science.Christi J. Guerrini,Jorge L. Contreras,Whitney Bash Brooks,Isabel Canfield,Meredith Trejo &Amy L. McGuire -2022 -New Genetics and Society 41 (2):74-95.
    The perspectives of genomic citizen scientists on ownership of research outputs are not well understood, yet they are useful for identifying alignment of participant expectations and project practices and can help guide efforts to develop innovative tools and strategies for managing ownership claims. Here, we report findings from 52 interviews conducted in 2018 and 2019 to understand genomic citizen science stakeholders’ conceptualizations of, experiences with, and preferences for ownership of research outputs. Interviewees identified four approaches for recognizing genomic citizen scientists’ (...) ownership and related credit interests in research outputs: shared governance via commons models; fractional ownership of benefits; full and creative attribution; and offensive and defensive patenting. Interviewees also agreed that the model selected by any project should at least maximize access to research outputs and, as appropriate and to the extent possible, broadly distribute rights of control and entitlements to research benefits. (shrink)
    No categories
    Direct download(3 more)  
     
    Export citation  
     
    Bookmark  
  30.  62
    Currents in Contemporary Ethics: Meeting the Growing Demands of Genetic Research.Amy L. McGuire &Richard A. Gibbs -2006 -Journal of Law, Medicine and Ethics 34 (4):809-812.
    The promise of personalized medicine and the quest for a greater understanding of the genetic basis of disease has transformed the research enterprise. The Director of the National Institutes of Health, Elias A. Zerhouni, M.D., recently predicted “that comprehensive, genomics- based health care will become the norm, with individualized preventive medicine and early detection of illnesses.” This excitement about the potential scientific and clinical advances that may come from genomics- based research has led several NIH institutions to launch initiatives for (...) genome-wide association studies, calling on researchers and institutions to utilize the new DNA analysis technologies to study the genetic variation between individuals with a particular illness and healthy controls. (shrink)
    Direct download(3 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  31.  75
    The Ethical Health Lawyer.Amy L. McGuire,Mary A. Majumder &J. Richard Cheney -2005 -Journal of Law, Medicine and Ethics 33 (3):603-607.
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  32.  50
    Respect as an organizing normative category for research ethics.Amy L. McGuire &Laurence B. McCullough -2005 -American Journal of Bioethics 5 (1):W1 – W2.
    Rosamond Rhodes calls for a reconceptualization of research ethics and a fundamental shift in attitude toward both research subjects and scientific investigators. She recognizes the limits of the e...
    Direct download(4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  33.  20
    Clinical Integration of Next Generation Sequencing: A Policy Analysis.David Kaufman,Margaret Curnutte &Amy L. McGuire -2014 -Journal of Law, Medicine and Ethics 42 (s1):5-8.
    In 1996, President Clinton offered a promissory vision for human genetics when he said: “I think it won't be too many years before parents will be able to go home from the hospital with their newborn babies with a genetic map in their hands that will tell them, here's what your child's future will likely be like.”The rapid evolution of genetic sequencing technologies has advanced that vision. In October 2006, the cost of sequencing an entire human genome was $10.4 million; (...) by 2014 the cost had decreased a thousand fold. The term next generation sequencing describes a variety of laboratory methods that allow efficient determination of the precise order of nucleotides in a DNA sequence. The papers in this issue of the Journal of Law, Medicine & Ethics focus on “clinical NGS,” which refers to rapid DNA sequencing using second-, third- and fourth-generation sequencing technologies to perform genome-wide sequencing of multiple genes or alleles for clinical prognostic, diagnostic, and therapeutic purposes. (shrink)
    No categories
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  34.  2
    Embracing Epistemic Humility: Rethinking Psychedelic Exceptionalism Through Diverse Perspectives.Jarrel De Matas,Amy L. McGuire &Hasan Yasin -2025 -American Journal of Bioethics 25 (1):98-100.
    In their contribution to the rapidly developing field of research on psychedelic medicine, Glenn Cohen and Mason Marks shed light on a frequently overlooked but critical aspect of ethical considera...
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark  
  35.  74
    Currents in Contemporary Bioethics.Amy L. McGuire,Melody J. Wang &Frank J. Probst -2012 -Journal of Law, Medicine and Ethics 40 (4):1040-1046.
    Increasingly, genomic analysis is being utilized to diagnose children with developmental delay or dysmorphic facial features suggestive of a congenital disorder. Genetic testing has rapidly evolved, and the genome-wide tests that we use today are significantly different from the more targeted single-gene tests of the last decade. Chromosomal microarray analysis is now a first line test for children with multiple birth defects, children with intellectual impairment, and children with an unusual constellation of symptoms that do not fit with a known (...) disease. There are three types of CMA that are currently clinically available. CMA by oligonucleotide array-based comparative genomic hybridization compares the hybridization signal from the patient's DNA to that of a reference DNA sample for each oligonucleotide on the array. Depending on the specific array, this can range from tens of thousands to hundreds of thousands of oligonucleotides. (shrink)
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  36.  19
    Increasing physician participation as subjects in scientific and quality improvement research.Amy L. McGuire &Sylvia J. Hysong -2022 -BMC Medical Ethics 23 (1):1–4.
    Background The twenty-first century has witnessed an exponential increase in healthcare quality research. As such activities become more prevalent, physicians are increasingly needed to participate as subjects in research and quality improvement (QI) projects. This raises an important ethical question: how should physicians be remunerated for participating as research and/or QI subjects? Financial versus non-monetary incentives for participation Research suggests participation in research and QI is often driven by conditional altruism, the idea that although initial interest in enrolling in research (...) is altruistic or prosocial, decisions to actually perform study tasks are cost–benefit driven. Thus, the three models commonly employed to appropriately compensate participants (in-kind compensation such as travel reimbursement, paying market rates for the subject’s time, and paying market rates for the activity asked of the participant) are a poor fit when the participant is a clinician, largely due to the asymmetry between cost and benefit or value to the participant. Non-monetary alternatives such as protected time for participation, continuing education or maintenance of certification credit, or professional development materials, can provide viable avenues for reducing this asymmetry. Conclusion Research and QI are integral to the betterment of medicine and healthcare. To increase physician participation in these activities as the subject of study, new models are needed that clarify the physician’s role in research and QI as a subject. Non-monetary approaches are recommended to successfully and ethically encourage research and QI participation, and thus incorporate these activities as a normal part of the ethical clinician’s and successful learning healthcare system’s world view. (shrink)
    No categories
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark  
  37.  34
    Ethical and Legal Challenges Associated with Public Molecular Autopsies.Quianta L. Moore,Mary A. Majumder,Lindsey K. Rutherford &Amy L. McGuire -2016 -Journal of Law, Medicine and Ethics 44 (2):309-318.
    There is a national movement supporting the retention and use of bio-specimens from deceased individuals for the purpose of genetic testing. This manuscript discusses the significance of postmortem genetic testing in the context of death determination by medical examiners. We highlight distinctive concerns that are raised in the areas of consent, confidentiality, and return of results when genetic testing is performed as part of a public molecular autopsy. We believe our manuscript will contribute to the development of a robust ethical (...) and legal framework for genetic testing in this context. (shrink)
    No categories
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark  
  38.  19
    Learning Health System — Moving from Ethical Frameworks to Practical Implementation.Stephanie R. Morain,Mary A. Majumder &Amy L. McGuire -2019 -Journal of Law, Medicine and Ethics 47 (3):454-458.
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark  
  39.  31
    Pediatric Cancer Genetics Research and an Evolving Preventive Ethics Approach for Return of Results after Death of the Subject.Sarah Scollon,Katie Bergstrom,Laurence B. McCullough,Amy L. McGuire,Stephanie Gutierrez,Robin Kerstein,D. Williams Parsons &Sharon E. Plon -2015 -Journal of Law, Medicine and Ethics 43 (3):529-537.
    The return of genetic research results after death in the pediatric setting comes with unique complexities. Researchers must determine which results and through which processes results are returned. This paper discusses the experience over 15 years in pediatric cancer genetics research of returning research results after the death of a child and proposes a preventive ethics approach to protocol development in order to improve the quality of return of results in pediatric genomic settings.
    Direct download(2 more)  
     
    Export citation  
     
    Bookmark  
  40.  215
    “Snake-oil,” “quack medicine,” and “industrially cultured organisms:” biovalue and the commercialization of human microbiome research. [REVIEW]Melody J. Slashinski,Sheryl A. McCurdy,Laura S. Achenbaum,Simon N. Whitney &Amy L. McGuire -2012 -BMC Medical Ethics 13 (1):28-.
    Background Continued advances in human microbiome research and technologies raise a number of ethical, legal, and social challenges. These challenges are associated not only with the conduct of the research, but also with broader implications, such as the production and distribution of commercial products promising maintenance or restoration of good physical health and disease prevention. In this article, we document several ethical, legal, and social challenges associated with the commercialization of human microbiome research, focusing particularly on how this research is (...) mobilized within economic markets for new public health uses. Methods We conducted in-depth, semi-structured interviews (2009–2010) with 63 scientists, researchers, and National Institutes of Health project leaders (“investigators”) involved with human microbiome research. Interviews explored a range of ethical, legal, and social dimensions of human microbiome research, including investigators’ perspectives on commercialization. Using thematic content analysis, we identified and analyzed emergent themes and patterns. Results Investigators discussed the commercialization of human microbiome research in terms of (1) commercialization, probiotics, and issues of safety, (2) public awareness of the benefits and risks of dietary supplements, and (3) regulation. Conclusion The prevailing theme of ethical, legal, social concern focused on the need to find a balance between the marketplace, scientific research, and the public’s health. The themes we identified are intended to serve as points for discussions about the relationship between scientific research and the manufacture and distribution of over-the-counter dietary supplements in the United States. (shrink)
    Direct download(10 more)  
     
    Export citation  
     
    Bookmark   3 citations  
Export
Limit to items.
Filters





Configure languageshere.Sign in to use this feature.

Viewing options


Open Category Editor
Off-campus access
Using PhilPapers from home?

Create an account to enable off-campus access through your institution's proxy server or OpenAthens.


[8]ページ先頭

©2009-2025 Movatter.jp